公开(公告)号：US20080008681A1

公开(公告)日：2008-01-10

申请号：US11768712

申请日：2007-06-26

申请人： Deqiang Niu ,  Dong Liu ,  Joel Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

发明人： Deqiang Niu ,  Dong Liu ,  Joel Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/21 ,  A61K31/498 ,  A61P31/12 ,  C07D245/04

CPC分类号： C07D245/04 ,  A61K38/212 ,  A61K38/215 ,  C07D403/12 ,  A61K2300/00

摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20060252713A1

公开(公告)日：2006-11-09

申请号：US11416739

申请日：2006-05-03

申请人： Yonghua Gai ,  Datong Tang ,  Ying Sun ,  Zhigang Chen ,  Yat Or ,  Zhe Wang

发明人： Yonghua Gai ,  Datong Tang ,  Ying Sun ,  Zhigang Chen ,  Yat Or ,  Zhe Wang

IPC分类号： A61K31/7048 ,  C07H17/08

CPC分类号： C07H17/08

摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

公开(公告)号：US08962551B2

公开(公告)日：2015-02-24

申请号：US12327538

申请日：2008-12-03

申请人： Deqiang Niu ,  Dong Liu ,  Joel D. Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

发明人： Deqiang Niu ,  Dong Liu ,  Joel D. Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/00 ,  A01N37/18 ,  C07D487/04 ,  A61K38/21 ,  C07K5/078 ,  C07K5/087

CPC分类号： C07D487/04 ,  A61K38/212 ,  A61K38/215 ,  C07K5/06165 ,  C07K5/0812 ,  A61K2300/00

摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

摘要翻译： 本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20070299078A1

公开(公告)日：2007-12-27

申请号：US11768723

申请日：2007-06-26

申请人： Deqiang Niu ,  Dong Liu ,  Joel Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Or ,  Zhe Wang

发明人： Deqiang Niu ,  Dong Liu ,  Joel Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Or ,  Zhe Wang

IPC分类号： A61K31/498 ,  A61K31/4985 ,  A61P31/12 ,  C07D245/04

CPC分类号： C07D245/04 ,  A61K38/212 ,  A61K38/215 ,  C07D403/12 ,  A61K2300/00

摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US07312201B2

公开(公告)日：2007-12-25

申请号：US11302525

申请日：2005-12-13

申请人： Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Yat Sun Or ,  Zhe Wang

发明人： Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K31/70 ,  C07H17/08

CPC分类号： C07H17/08

摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

公开(公告)号：US20060148731A1

公开(公告)日：2006-07-06

申请号：US11302529

申请日：2005-12-13

申请人： Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Zhigang Chen ,  Yat Or ,  Zhe Wang

发明人： Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Zhigang Chen ,  Yat Or ,  Zhe Wang

IPC分类号： A61K31/7052 ,  C07H17/08

CPC分类号： C07H17/08

摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

公开(公告)号：US09796754B2

公开(公告)日：2017-10-24

申请号：US14122672

申请日：2012-05-24

申请人： Zhenwei Miao ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Marsden ,  Jason Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Delia Ianina Lopez De Valenta

发明人： Zhenwei Miao ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Marsden ,  Jason Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Delia Ianina Lopez De Valenta

IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K5/103 ,  C07D207/08 ,  C07D401/12 ,  C07D417/12 ,  A61K47/48 ,  C07K5/02 ,  A61K38/07 ,  C07K5/062

CPC分类号： C07K5/101 ,  A61K38/07 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6861 ,  C07D207/08 ,  C07D401/12 ,  C07D417/12 ,  C07K5/0205 ,  C07K5/06043

摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

公开(公告)号：US20090047248A1

公开(公告)日：2009-02-19

申请号：US11835657

申请日：2007-08-08

申请人： Ying Sun ,  Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K31/4192 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/21 ,  A61P31/00 ,  C07D487/04

CPC分类号： C07D487/04 ,  A61K31/4192 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/21 ,  C07D471/04 ,  A61K2300/00

摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

摘要翻译： 本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20080038225A1

公开(公告)日：2008-02-14

申请号：US11835157

申请日：2007-08-07

申请人： Ying Sun ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K31/425 ,  A61K31/41 ,  A61K31/44 ,  A61K31/7056 ,  A61K38/21 ,  A61P31/12 ,  C07D249/04 ,  C07D277/30 ,  C07D401/12

CPC分类号： C07K5/0804 ,  A61K38/00 ,  C07D207/24 ,  C07D409/14 ,  C07D417/04 ,  C07D417/14

摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

摘要翻译： 本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20070281885A1

公开(公告)日：2007-12-06

申请号：US11759080

申请日：2007-06-06

申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/12 ,  C07K5/12

CPC分类号： A61K38/4886 ,  A61K38/21 ,  A61K38/212 ,  A61K38/215 ,  A61K38/45 ,  A61K38/52 ,  C07K5/0804 ,  C07K5/0812 ,  C07K7/06 ,  A61K2300/00

摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。